Skip to content

A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients

Safety and Efficacy of Remazolam in Gastroenteroscopy in Elderly Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05103696
Enrollment
120
Registered
2021-11-02
Start date
2021-10-01
Completion date
2023-03-30
Last updated
2023-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly Patients, Etomidate Combined With Propofol, Gastrointestinal Endoscopy, Remimazolam Besylate

Keywords

Remimazolam Besylate, Etomidate combined with propofol, Gastrointestinal Endoscopy

Brief summary

Studies have shown that etomidate combined with propofol in gastroscopy has high safety and lower incidence of hypoxia and hypotension, suggesting the advantages of etomidate combined with propofol in elderly patients. Remimazolam Besylate is a 1.1 class new drug that acts on GABA receptors and is metabolized by plasma esterase with fast metabolism time, only 1/7 of midazolam, which may be more suitable for elderly patients. Therefore, this study intends to explore the safety and effectiveness of two sedation schemes in gastroenteroscopy for elderly patients.

Detailed description

Before starting the endoscopy procedures, patients were randomly assigned to either Remimazolam Besylate group or propofol combined with etomidate group. The onset time, recovery time, vital signs, postoperative recovery, cognitive function and adverse events were compared.

Interventions

DRUGRemimazolam Besylate

Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min

Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with asAI-II indications for painless gastroenteroscopy and receiving diagnostic or therapeutic gastroenteroscopy; 2. Aged 60-75, body mass index (BMI) 19-28 kg/m2, Systolic blood pressure of 90-140mmHg, diastolic blood pressure of 50-90mmHg, resting heart rate of 50-100bpm and blood pulse oxygen saturation ≥95%

Exclusion criteria

1. Those who are refused to be included; 2. Those who are allergic to the drugs used in this study; 3. Epilepsy and other mental illnesses, a history of addiction such as opiates and other analgesics and/or tranquilizers (hypnotics); 4. Severe lung infection or upper respiratory tract infection; 7\. Sleep apnea syndrome, difficult airway (Mallampati score of 3 or 4) or asthma status; 8. Advanced cancer accompanied by extensive intra-abdominal metastasis;

Design outcomes

Primary

MeasureTime frameDescription
induction timeday 0The time from the beginning of the drug injection to the time when the patient does not respond to the verbal call
Recovery timeday 0First of 3 consecutive MOAA/S scores of 5 after the last injection of study drug
Modified Observer's Assessment of Alertness/Sedation[MOAA/S]day 0MOAA/S score ranges from 0 to 5 points, 0 point means patients do not respond to noxious stimulation; 5 point means patients responds readily to name spoken in normal tone. When the Modified Observer's Assessment of Alertness/ Sedation \[MOAA/S\] ≤4 that patients are sufficiently sedated.
Observation time in the PACUday 0the time interval between endoscope removal and departure from the recovery room (PADS score≥9)

Secondary

MeasureTime frameDescription
Simple Intelligence Assessment Scale (mini-cog)Every 4 hours, up to 1 week1. Ask the subjects to listen carefully and memorize 3 unrelated words, and then repeat (Apple, Watch, Coin); 2. Ask the subjects to draw the shape of the clock on a blank sheet of paper, and give the subject a time to mark it on the clock (the CDT of the clock drawing test is correct; it can correctly indicate the sequence of the digits and display the given Fixed time); 3. Ask the subject to say the 3 words given previously.
Drug dosagesday 0The total single dosage of remimazolam , propofol, etomidate,remifentanil and tosilate.
Patient overall satisfaction and surgeon satisfaction scoreday 0The patient's overall satisfaction score and surgeon satisfaction score were evaluated by 1-10 points (1mm=completely dissatisfied, 100mm=completely satisfied).
Visual analogue scale (VAS)day 0The visual analogue scale (VAS) score ranges from 0 to 10 points (0mm means patients feel no pain, 100mm means patients feel the most severe pain imaginable)
Level of hypoxiaday 0Oxygen saturation \<90% for more than 1 minute #that share a common Unit of Measure in(%)
Respiratory depressionday 0Respiratory rate \< 8 breaths per minute ,that share a common Unit of Measure in(times)
Rate of nause、vomiting、 dizziness、hiccups、 cough choking 、body movementWithin 24 hoursRate of nause、vomiting、 dizziness、hiccups、 cough choking 、body movement in (%) Rate of coughing and vomiting in(%)
Supine heart rate[HR]day 0Supine heart rate\[HR\] in (times)
Systolic, diastolic, blood pressureday 0Systolic, diastolic, blood pressure in(mmHg)
Assessment of pulse oximetry measurements[SpO2]day 0Assessment of pulse oximetry measurements\[SpO2\]in(%)
Respiration rate[RR]day 0Respiration rate\[RR\] in (times)
End-tidal carbon dioxide [EtCO2]day 0End-tidal carbon dioxide \[EtCO2\] in (%)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026